AMG 171 / Amgen - LARVOL DELTA

Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity (clinicaltrials.gov) - P1; N=60; Terminated; Sponsor: Amgen; Trial completion date: Apr 2022 ➔ Sep 2021; Recruiting ➔ Terminated; Trial primary completion date: Apr 2022 ➔ Sep 2021; Amgen determined the totality of the data does not support continuation of AMG 171 development program for treatment of Obesity. No safety concerns identified.

Clinical • Trial completion date • Trial primary completion date • Trial termination • Genetic Disorders • Obesity

Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Amgen; Trial completion date: Aug 2021 ➔ Apr 2022; Trial primary completion date: Aug 2021 ➔ Apr 2022

Clinical • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity (clinicaltrials.gov) - P1; N=48; Recruiting; Sponsor: Amgen; N=148 ➔ 48; Trial completion date: Mar 2022 ➔ Aug 2021; Trial primary completion date: Mar 2022 ➔ Aug 2021

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity (clinicaltrials.gov) - P1; N=148; Recruiting; Sponsor: Amgen; Trial completion date: Sep 2022 ➔ Dec 2021; Trial primary completion date: Sep 2022 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date